Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1973
|
| gptkbp:ATCCode |
gptkb:J01DB04
|
| gptkbp:brand |
gptkb:cefazolin
|
| gptkbp:CASNumber |
25953-19-9
|
| gptkbp:chemicalFormula |
C14H14N8O4S3
|
| gptkbp:contraindication |
hypersensitivity to cephalosporins
|
| gptkbp:discoveredBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:drugClass |
first-generation cephalosporin
|
| gptkbp:eliminationHalfLife |
1.8 hours
|
| gptkbp:excretion |
renal
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ancef
|
| gptkbp:indication |
urinary tract infection
respiratory tract infection skin infection surgical prophylaxis bone and joint infection |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits bacterial cell wall synthesis
|
| gptkbp:molecularWeight |
454.5 g/mol
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
intramuscular
intravenous |
| gptkbp:sideEffect |
nausea
diarrhea allergic reaction rash |
| gptkbp:synonym |
gptkb:Kefzol
cefazolin sodium |
| gptkbp:usedFor |
gptkb:Bacteria
|
| gptkbp:bfsParent |
gptkb:cefazolin
|
| gptkbp:bfsLayer |
7
|